About
Chong Xu is a Partner at F-Prime focused on biopharmaceutical and medical technology, and collaborates with the Eight Roads Ventures Asia team on portfolio and investment opportunities in China. He joined F-Prime in 2015 after roles at McKinsey, hedge funds Massif Partners and Affirmed Healthcare, and neurobiology research at Temasek Life Sciences Laboratory; he holds a PhD in Cell Biology and an MBA from the University of Virginia and a biology degree from Zhejiang University.
Invests in
BiotechMedical Devices
Experience
- F-Prime CapitalPartnercurrent2015 — presentGreater Boston Area
- University of Virginia Darden School of BusinessAlumni Boardcurrent2025 — present
- Focus BioMember Board of Directorscurrent2025 — present
- OnCusp TherapeuticsDirector Board of Directorscurrent2024 — present
- K36 Therapeutics, Inc.Director Board Of Directorscurrent2021 — presentBoston, Massachusetts, United States
- SironaxMember Board of Directorscurrent2019 — present
- Citrine Medicine / RareStone GroupDirector Board Of Directorscurrent2019 — present
- Geneception (Shanghai) Bio-technology Co.,Ltd. / Skyline TherapeuticsCo-Founder, Investor, Board Directorcurrent2019 — present
- LenoMedBoard Observercurrent2020 — present
- Yisheng GroupBoard Observer2015 — 2021
- AdageneDirector Board Of Directors2020 — 2021
- Eyebright Medical TechnologyBoard Observer2015 — 2020
- Semma TherapeuticsBoard Observer2017 — 2019
- Innovent Biologics（信达生物制药）Board Observer2015 — 2018
- McKinsey & CompanyAssociate2014 — 2015Greater Boston Area
- Darden School of BusinessMBA Class Of 20142012 — 2014Charlottesville, Virginia
- Massif PartnersDirector2011 — 2012Greenwich, CT
- Affirmed Capital LLCHealthcare Equity Analyst2009 — 2011
- Cell Biology, University of VirginiaGraduate Research2002 — 2009
- A*STAR/Temasek Life Sciences Laboratory (Former Institute of Molecular Agrobiology)Assistant Research Officer2001 — 2002
Skills & more
Healthcare7Life Sciences9Financial Analysis22Due Diligence5Financial Modeling21Market Research7Biotechnology16Molecular Biology35Research20Cell Biology15Biochemistry20Pharmaceuticals1
+4 more
OncologyEquity Researchinvestment analysisProblem SolvingLanguages Chinese · English
From Chong's professional profile.
Investments
Investor
AlphaGen TxK36 TxPediatrixRareStone GroupSkyline Tx
Per the firm's website.
Colleagues at F-Prime Capital
Abby Wagner
Senior Accountant at F-Prime Capital Partners
Abdul Abdirahman
Principal at F-Prime Capital Partners
Alex Pasteur
Partner at F-Prime Capital Partners
Allan Galper
Vice President & Associate General Counsel at F-Prime Capital Partners
Allison MacLeod
Venture Partner at F-Prime Capital Partners
Amber Cai
Venture Partner at F-Prime Capital Partners
Amrit Jalan
Investor at Fine Structures Ventures
Andrew Bognanni
Director of Finance at F-Prime Capital Partners
Network4
Abdul Abdirahman
Principal at F-Prime Capital Partners
Alex Pasteur
Partner at F-Prime Capital Partners
Bala Varadhan
Principal at F-Prime Capital Partners
Betsy Mulé
Principal at F-Prime Capital Partners
Investors connected to Chong in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Chong Xu?
- Chong Xu is a Partner at F-Prime focused on biopharmaceutical and medical technology, and collaborates with the Eight Roads Ventures Asia team on portfolio and investment opportunities in China. He joined F-Prime in 2015 after roles at McKinsey, hedge funds Massif Partners and Affirmed Healthcare, and neurobiology research at Temasek Life Sciences Laboratory; he holds a PhD in Cell Biology and an MBA from the University of Virginia and a biology degree from Zhejiang University.
- Where does Chong Xu work?
- Chong Xu is Partner at F-Prime Capital.
- What does Chong Xu invest in?
- Chong Xu invests in Biotech, Medical Devices.
- What check size does Chong Xu write?
- Chong Xu typically writes checks of $100K – $10M.
- What boards does Chong Xu sit on?
- Chong Xu holds tracked board seats at Adagene, Innovent, OnCusp Tx, Remunix, Semma Tx, Shinobi Tx, Sironax.
- What companies has Chong Xu invested in?
- Investments tracked here include AlphaGen Tx, K36 Tx, Pediatrix, RareStone Group, Skyline Tx.
- Where did Chong Xu go to school?
- Chong Xu studied at University of Virginia Darden School of Business (Master of Business Administration (MBA), Business Administration and Management); University of Virginia (Ph.D., Cell Biology); National University of Singapore (Visiting Student, Institute of Molecular Agrobiology).
Same school
Also attended University of Virginia Darden School of Business156
Cathy FriedmanInvestor at GV (Google Ventures)Dan LynchInvestor at GV (Google Ventures)Rajan MehraPartner at March Capital PartnersRob LudwigChief Operating Officer at Hoxton VenturesWilliam RobertsTreasurer at Maryland TEDCOJamie SerioVice President, Ventures at Capital Factory
+ 150 more
Also attended University of Virginia565
Alexis OhanianFounder & General Partner of Seven Seven SixAndy FligelSenior Managing Director at Intel CapitalKandace ElamVice President of GTM Talent at Menlo VenturesTrevor KienzleInvestor at Correlation VenturesFrank RotmanCo-Founder and Partner Emeritus at QED InvestorsMegan LightcapPartner, Creator Fund at Slow Ventures
+ 559 more
Also attended National University of Singapore442
Justin HallPartner at Golden Gate VenturesMahati SridharPartner, Rise of the Rest at RevolutionCeline XiaoInvestor at DN CapitalSofia DahouneInvestor at DaphniYi Min LohInvestment Associate at Burda Principal InvestmentsSean LooInvestment Analyst at Burda Principal Investments
+ 436 more
Also attended Zhejiang University37
Albert WangSenior Director at Qualcomm VenturesEnrique OtiInvestor at Green FlagHong TangVenture Partner at Foothill VenturesTony GuGeneral Partner at NGC VenturesSophie WatsonVenture Debt Fund at Salica InvestmentsShu CaoManaging Director at Heuristic Capital Partners
+ 31 more
Shared employers
Also worked at University of Virginia Darden School of Business10
Ned HooperPartner at Centerview Capital TechnologyMarc-André MarcottePartner and Head of Venture Capital at Sectoral Asset ManagementSimon GregoryPartner, Chief Compliance Officer at SoftBank Vision FundAndrea BarriosInvestment Principal at Sandpiper VenturesAlok SomaniCFO at OrbitPascal G BouvierSenior Practitioner Advisor at SC Ventures
+ 4 more
